Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa
JE Swatton, PW Davenport, EA Maunders, JL Griffin, KS Lilley, M Welch
PLoS One | PUBLIC LIBRARY SCIENCE | Published : 2016
The macrolide antibiotic, azithromycin (AZM), has been reported to improve the clinical outcome of cystic fibrosis patients, many of whom are chronically-infected with Pseudomonas aeruginosa. However, the highest clinically-achievable concentrations of this drug are well-below the minimum inhibitory concentration for P. aeruginosa, raising the question of why AZM exhibits therapeutic activity. One possibility that has been raised by earlier studies is that AZM inhibits quorum sensing (QS) by P. aeruginosa. To explicitly test this hypothesis the changes brought about by AZM treatment need to be compared with those associated with specific QS mutants grown alongside in the same growth medium, ..View full abstract
Awarded by Biotechnology and Biological Sciences Research Council
Awarded by Medical Research Council
This work was funded by grants (BB/C/500252/1) and (BB/M019411/1) from the Biotechnology and Biological Sciences Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.The authors have no conflicting financial interests. This work was supported by the BBSRC (UK). Pfizer (UK) is thanked for generously supplying azithromycin.